Recurrent Prostate Cancer
118
11
16
69
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
47 trials with published results (40%)
Research Maturity
69 completed trials (58% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.6%
16 terminated out of 118 trials
81.2%
-5.4% vs benchmark
3%
4 trials in Phase 3/4
68%
47 of 69 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 69 completed trials
Clinical Trials (118)
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
PSMA-PET Registry for Recurrent Prostate Cancer
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
Partial Prostate Salvage High Dose Rate Brachytherapy
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores